الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 162 |  |  |
| | | from | 162 | | |
Abstract
Breast cancer is considered one of the most persistent cancers among women globally. Specifically, Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer considering its invading nature, high heterogeneity and ineffective treatment options.
The conventional types of treatment for TNBC are surgery, radiation therapy (RT) and chemotherapy (CT).
Despite being the first line treatment for TNBC, chemotherapy have encountered some disadvantages including negative side effects, multi-drug resistance and rapid clearance from the circulation, which limited the effect of these agents. Various approaches were adopted to solve problems associated with TNBC treatment. Molecular targeted anti-cancer agents are actually one of the promising approaches in which more specific effects on cancer cells are encountered and a much lower level of adverse reactions are achievable.
In addition, combining two or more of these agents can be synergistic with the ability to overcome resistance mechanisms. Another approach that proved effectiveness against TNBC is gas therapy.
Agents with gas-releasing abilities have a good record of chemoprevention and anti-cancer activity.
On the other hand, nanoparticles (NPs) show interesting characteristics as small sizes, large surface-to-volume ratios, high drug loading, self-assembly capacity, and biocompatibility.
Thus, they confer specific physical and chemical properties at the cellular and molecular levels not attainable with the drug moieties themselves.